Cover Image

Nivolumab as a promising treatment option for metastatic salivary duct carcinoma

Salivary duct carcinomas (SDC) of the parotid gland are rarely occurring highly malignant tumors. A 65-year-old man presented with a preauricular mass. After surgical treatment and histologic examination, the findings were interpreted as a squamous cell carcinoma (SCC) metastasis of the parotid glan...

Full description

Saved in:
Bibliographic Details
Main Authors: Bugia, Luis (Author) , Jungbauer, Frederic (Author) , Zaubitzer, Lena (Author) , Hörner, Christian (Author) , Merx, Kirsten (Author) , Yasser, Abo-Madyan (Author) , Germann, Thomas (Author) , Lammert, Anne (Author) , Scherl, Claudia (Author) , Rotter, Nicole (Author) , Affolter, Annette (Author)
Format: Article (Journal)
Language:English
Published: September 2024
In: Journal of immunotherapy
Year: 2024, Volume: 47, Issue: 7, Pages: 258-262
ISSN:1537-4513
DOI:10.1097/CJI.0000000000000513
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1097/CJI.0000000000000513
Verlag, kostenfrei, Volltext: https://journals.lww.com/immunotherapy-journal/fulltext/2024/09000/nivolumab_as_a_promising_treatment_option_for.4.aspx
Get full text
Author Notes:Luis Bugia, Frederic Jungbauer, Lena Zaubitzer, Christian Hörner, Kirsten Merx, Abo-Madyan Yasser, Thomas Germann, Anne Lammert, Claudia Scherl, Nicole Rotter, and Annette Affolter
Description
Summary:Salivary duct carcinomas (SDC) of the parotid gland are rarely occurring highly malignant tumors. A 65-year-old man presented with a preauricular mass. After surgical treatment and histologic examination, the findings were interpreted as a squamous cell carcinoma (SCC) metastasis of the parotid gland deriving from a cancer of unknown primary DD primary SCC of the parotid gland. Adjuvant platinum-based radiochemotherapy was administered in domo. However, re-staging revealed multiple size-progressive pulmonary round lesions. After resection and histological examination of a pulmonary mass and in synopsis with the primary tumor, the initial diagnosis of SCC was revised to SDC of the parotid gland. With positive HER-2 status, off-label trastuzumab/docetaxel was initiated in an individual healing attempt, during which the pulmonary metastases showed clear progression. Consequently, the patient received immunotherapy with nivolumab according to his negative PD-L1 status. After 57 cycles of nivolumab, the patient presents with partial remission and in good condition. We report, for the first time, a robust response of metastatic SDC to checkpoint inhibition with nivolumab without additional radiotherapy.
Item Description:Gesehen am 18.11.2024
Physical Description:Online Resource
ISSN:1537-4513
DOI:10.1097/CJI.0000000000000513

Similar Items